ROCKWELL MEDICAL, INC.

Drug pipeline (3)

Asset	Stage	Revenue	Trials	Status
CALCITRIOL	approved	—	0	—
TRIFERIC	approved	—	12	approved
TRIFERIC AVNU	approved	—	12	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (19)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT01920854	phase1	completed	2013-06-01	2013-09-01	Rockwell Medical Technologies, Inc.	A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.
NCT04042324	phase1_2	completed	2019-09-30	2020-01-16	Rockwell Medical Technologies, Inc.	A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
NCT01320202	phase3	completed	2011-03-01	2013-05-01	Rockwell Medical Technologies, Inc.	Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
NCT01286012	phase2	completed	2011-01-01	2013-01-01	Rockwell Medical Technologies, Inc.	Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
NCT01322347	phase3	completed	2011-04-01	2014-01-01	Rockwell Medical Technologies, Inc.	Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)

FDA applications (4)

Application

Approved

Type

Applicant

Products

NDA 212860

2020-03-27

NDA

ROCKWELL MEDICAL INC

NDA 208551

2016-04-25

NDA

ROCKWELL MEDICAL INC

NDA 206317

2015-01-23

NDA

ROCKWELL MEDICAL INC

ANDA 076206

2003-09-17

ANDA

ROCKWELL MEDICAL TECHNOLOGIES INC